ArticleClinical and diagnostic laboratory immunology2005
Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay.
Article in Clinical and diagnostic laboratory immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Diagnostic accuracy of IL-2 for the diagnosis of latent tuberculosis: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014Pooled it
- Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study.PloS one · 2008Trial
- Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals.The Journal of clinical investigation · 2021Article
- Validation and Optimization of Host Immunological Bio-Signatures for a Point-of-Care Test for TB Disease.Frontiers in immunology · 2021Article
- Changes in cytokine responses to TB antigens ESAT-6, CFP-10 and TB 7.7 and inflammatory markers in peripheral blood during therapy.Scientific reports · 2018Article
- Celiac disease: from etiological factors to evolving diagnostic approaches.Journal of gastroenterology · 2017Review
- Close contact interferon-gamma response to the new PstS1BMC research notes · 2017Article
- Evaluation of Mycobacterium tuberculosis Early Secreted Antigenic Target 6 Recombinant Protein as a Diagnostic Marker in Skin Test.Osong public health and research perspectives · 2015Article
- Ex-vivo whole blood secretion of interferon (IFN)-γ and IFN-γ-inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN-γ enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigen (HLA)-DQ2·5(+) -associated coeliac disease.Clinical and experimental immunology · 2014Article
- Diagnosis of Coxiella burnetii infection: comparison of a whole blood interferon-gamma production assay and a Coxiella ELISPOT.PloS one · 2014Article
- Mycobacterium tuberculosis region of difference (RD) 2 antigen Rv1985c and RD11 antigen Rv3425 have the promising potential to distinguish patients with active tuberculosis from M. bovis BCG-vaccinated individuals.Clinical and vaccine immunology : CVI · 2013Article
- Evaluation of a tuberculosis whole-blood interferon-γ chemiluminescent immunoassay among Chinese military recruits.Molecular diagnosis & therapy · 2011Article
- Suppressed type 1, type 2, and type 17 cytokine responses in active tuberculosis in children.Clinical and vaccine immunology : CVI · 2011Article
- Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery.Clinical microbiology reviews · 2011Review
- Increased risk of tuberculosis after gastrectomy and chemotherapy in gastric cancer: a 7-year cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2011Article
- Interferon-γ and proliferation responses to Salmonella enterica Serotype Typhi proteins in patients with S. Typhi Bacteremia in Dhaka, Bangladesh.PLoS neglected tropical diseases · 2011Article
- IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy.BMC infectious diseases · 2011Article
- Clinical evaluation of a homemade enzyme-linked immunospot assay for the diagnosis of active tuberculosis in China.Molecular biotechnology · 2011Article
- Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons?PloS one · 2010Article
- Understanding latent tuberculosis: a moving target.Journal of immunology (Baltimore, Md. : 1950) · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We recently set up a gamma interferon (IFN-gamma) enzyme-linked immunospot assay (ELISPOT), using selected early secreted antigenic target 6 (ESAT-6) peptides, that appears specific for active tuberculosis (A-TB). However, ELISPOT is difficult to automate. Thus, the objective of this study was to determine if the same selected peptides may be used in a technique more suitable for routine work in clinical laboratories, such as whole-blood enzyme-linked immunosorbent assay (WBE). For this purpose, 27 patients with A-TB and 41 control patients were enrolled. Our WBE, using the already described selected peptides from ESAT-6 plus three new ones from culture filtrate protein 10, was performed, and data were compared with those obtained by ELISPOT. Using our selected peptides, IFN-gamma production, evaluated by both WBE and ELISPOT, was significantly higher in patients with A-TB than in controls (P < 0.0001). Statistical analysis showed a good correlation between the results obtained by WBE and ELISPOT (r = 0.80, P < 0.001). To substantiate our data, we compared our WBE results with those obtained by QuantiFERON-TB Gold, a whole-blood assay based on region of difference 1 (RD1) overlapping peptides approved for TB infection diagnosis. We observed a slightly higher sensitivity with QuantiFERON-TB Gold than with our WBE (89% versus 81%); however, our test provided a better specificity result (90% versus 68%). In conclusion, results obtained by WBE based on selected RD1 peptides significantly correlate with those generated by ELISPOT. Moreover, our assay appears more specific for A-TB diagnosis than QuantiFERON-TB Gold, and thus it may represent a complementary tool for A-TB diagnosis for routine use in clinical laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.